Skip to content

Post Discharge Human Milk Fortifier in Preterm Infants

Growth and Development in Preterm Infants Fed Human Milk Containing a Powdered Human Milk Fortifier (HMF) Post Hospital Discharge

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00413985
Enrollment
40
Registered
2006-12-20
Start date
2004-01-31
Completion date
Unknown
Last updated
2013-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant, Low Birth Weight

Keywords

Low Birth Weight, Fortified Human Milk, breastfeeding, infants, growth

Brief summary

The purpose of this study is to determine whether low birth weight (LBW) infants fed human milk (HM)supplemented with a specially designed powdered human milk fortifier until 12 weeks after hospital discharge will have better growth and neurodevelopment than infants fed HM alone.

Detailed description

Consensus exists in the literature that a significant proportion of low birth weight (LBW, \<1800 g) infants leave hospital with overt signs of under-nutrition (eg. growth retardation). Recent evidence from randomized control trials suggest that provision of nutrient-enriched feeding to formula-fed premature infants after hospital discharge improves their growth, accretion of lean body mass and bone mineral content compared to infants fed a standard term formula. While available data suggest an advantage of human milk feeding after hospital discharge, experimental evidence on which to base guidelines to enrich, or not to enrich, human milk (HM) are notably absent.

Interventions

DRUGNutrient-enriched human milk

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 4 Months
Healthy volunteers
No

Inclusion criteria

* Birth Weight between 750-1800 g * Gestational Age at birth between 26 and 32 weeks * Singleton or twin birth (for twins to be eligible, both must meet eligibility criteria) * Small for Gestational age or appropriate for gestational age * ≥ 80% energy received from human milk in the previous three days * ≥ 25% of human milk consumed orally in the previous three days * Mother agrees to exclusively feed her infant human nilk after discharge * If so randomized, parents agree to supplement \ 1/2 or the human milk provided to her infant as powdered human milk fortifier for 12 weeks after hospital discharge * Subject's parents have voluntarily signed an informed consent form

Exclusion criteria

* Serious congenital or chromosomal anomalies that will affect growth * Grade III or IV periventricular/intraventricular hemorrhage * Received steroids within 14 days o randomization * Asphyxia (hypoxia or ischemia) es evident by severe and permanent neurological data * Maternal incapacity, including maternal cocaine or alcohol abuse dring pregnancy, or concurrent, or mother or infant has tested positive for HIV * Principal residence of study family outside GTA * Mother unable to verbally communicate in English * A single feeding must be fortified \> 24 kcal/oz or \>50% of feeds need to be fortified

Design outcomes

Primary

MeasureTime frame
Growth (weight, length and head circumference)
Body composition (fat-free mass, whole body mineral content, fat mass
Milk consumption
Estimated energy and nutrient intakes
Duration/exclusivity of breastfeeding
Morbidity (serious adverse events, hospital re-admissions)
Development (mental, motor, visual and language)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026